| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Across the last three months, Biolife Solutions, Inc.'s insiders have reduced their positions by a net 1,200,000 shares worth roughly $28.1M.
Classified under Health Care Equipment & Supplies (Health Care sector), BLFS's insider flows are most useful compared with peers in the same group.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 4.76M | $164.88M | - | |
| CEO | 733.7K | $25.43M | - | |
| VP | 388.5K | $13.46M | - | |
| CFO | 213.2K | $7.39M | - | |
| Other | 162.6K | $5.64M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 3, 2022 | Mathew Aby J.68 | EVP &Chief Scientific Officer | Sale+OE | 19,837 | $28.83 | $571,875.12 | -4.6% | -51.5% | -5.5% | |
| Feb 1, 2022 | Rice Michael72 | CEO | Sale+OE | 16,666 | $29.90 | $498,313.40 | -6.0% | -56.6% | -22.6% | |
| Jan 20, 2022 | Aebersold Sarah60 | VP, Global Human Resources | Sell | 332 | $30.24 | $10,039.68 | -1.7% | -47.3% | -16.4% | |
| Jan 20, 2022 | Schulz Marcus71 | Chief Revenue Officer | Sell | 395 | $30.24 | $11,944.80 | -1.4% | -47.3% | -16.4% | |
| Jan 12, 2022 | Schulz Marcus71 | Chief Revenue Officer | Sell | 267 | $32.18 | $8,592.06 | -0.9% | -40.9% | -26.5% | |
| Jan 12, 2022 | Rice Michael72 | CEO | Sale+OE | 33,332 | $31.28 | $1,042,458.30 | -6.0% | -40.9% | -26.5% | |
| Jan 7, 2022 | De Greef Roderick74 | COO &President | Sell | 10,816 | $30.75 | $332,592.00 | -3.7% | -28.9% | -39.8% | |
| Jan 7, 2022 | Wichterman Troy60 | Chief Financial Officer | Sell | 47 | $30.75 | $1,445.25 | -0.2% | -28.9% | -39.8% | |
| Jan 5, 2022 | Mathew Aby J.68 | EVP &Chief Scientific Officer | Sale+OE | 17,857 | $34.73 | $620,095.10 | -4.2% | -30.5% | -44.6% | |
| Dec 29, 2021 | Mathew Aby J.68 | EVP &Chief Scientific Officer | Sell | 736 | $39.37 | $28,976.32 | -0.4% | -42.8% | -54.2% |